Healthcare - Biotechnology - NASDAQ - US
$ 3.54
1.43 %
$ 38.2 M
Market Cap
-1.99
P/E
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.[ Read More ]
The intrinsic value of one LTRN stock under the base case scenario is HIDDEN Compared to the current market price of 3.54 USD, Lantern Pharma Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart LTRN
FINANCIALS
0
REVENUE
-17.9 M
OPERATING INCOME
-16 M
NET INCOME
-14.3 M
OPERATING CASH FLOW
-930 K
INVESTING CASH FLOW
-500 K
FINANCING CASH FLOW
0
REVENUE
-5.18 M
OPERATING INCOME
-4.51 M
NET INCOME
-5.58 M
OPERATING CASH FLOW
680 K
INVESTING CASH FLOW
12 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Lantern Pharma Inc.
| Current Assets | 43.3 M |
| Cash & Short-Term Investments | 41.3 M |
| Receivables | 0 |
| Other Current Assets | 2.04 M |
| Non-Current Assets | 306 K |
| Long-Term Investments | 0 |
| PP&E | 280 K |
| Other Non-Current Assets | 25.9 K |
| Current Liabilities | 2.68 M |
| Accounts Payable | 0 |
| Short-Term Debt | 173 K |
| Other Current Liabilities | 2.51 M |
| Non-Current Liabilities | 61.5 K |
| Long-Term Debt | 61.5 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Lantern Pharma Inc.
| Revenue | 0 |
| Cost Of Revenue | 175 K |
| Gross Profit | -175 K |
| Operating Expenses | 17.9 M |
| Operating Income | -17.9 M |
| Other Expenses | -1.92 M |
| Net Income | -16 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-39.02%
ROE
-36.57%
ROA
-43.70%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lantern Pharma Inc.
| Net Income | -16 M |
| Depreciation & Amortization | 175 K |
| Capital Expenditures | -18.7 K |
| Stock-Based Compensation | 1.07 M |
| Change in Working Capital | 538 K |
| Others | 373 K |
| Free Cash Flow | -14.4 M |
Wall Street Analysts Price Targets
Lantern Pharma Inc.
LTRN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Lantern Pharma Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
378 K USD 2
6-9 MONTHS
1.35 M USD 2
9-12 MONTHS
1.49 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
5 months ago
May 23, 2024
|
Sell 43.4 K USD
|
Kreis Leslie W.
10 percent owner |
- 6944
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 87.9 K USD
|
Kreis Leslie W.
10 percent owner |
- 13888
|
6.33 USD |
|
5 months ago
May 23, 2024
|
Sell 13.3 K USD
|
Kreis Leslie W.
10 percent owner |
- 2126
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 26.9 K USD
|
Kreis Leslie W.
10 percent owner |
- 4253
|
6.33 USD |
|
5 months ago
May 23, 2024
|
Sell 5.81 K USD
|
Kreis Leslie W.
10 percent owner |
- 930
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 11.8 K USD
|
Kreis Leslie W.
10 percent owner |
- 1859
|
6.33 USD |
|
5 months ago
May 23, 2024
|
Sell 43.4 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 6944
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 87.9 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 13888
|
6.33 USD |
|
5 months ago
May 23, 2024
|
Sell 13.3 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 2126
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 26.9 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 4253
|
6.33 USD |
|
5 months ago
May 23, 2024
|
Sell 5.81 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 930
|
6.25 USD |
|
5 months ago
May 24, 2024
|
Sell 11.8 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 1859
|
6.33 USD |
|
8 months ago
Feb 27, 2024
|
Sell 153 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 34731
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 250 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 51608
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 66.7 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 13686
|
4.87 USD |
|
8 months ago
Feb 27, 2024
|
Sell 46.7 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 10620
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 76.5 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 15780
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 20.4 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 4185
|
4.87 USD |
|
8 months ago
Feb 27, 2024
|
Sell 20.5 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 4649
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 33.5 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 6909
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 8.92 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 1832
|
4.87 USD |
|
8 months ago
Feb 27, 2024
|
Sell 153 K USD
|
Kreis Leslie W.
10 percent owner |
- 34731
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 250 K USD
|
Kreis Leslie W.
10 percent owner |
- 51608
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 66.7 K USD
|
Kreis Leslie W.
10 percent owner |
- 13686
|
4.87 USD |
|
8 months ago
Feb 27, 2024
|
Sell 46.7 K USD
|
Kreis Leslie W.
10 percent owner |
- 10620
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 76.5 K USD
|
Kreis Leslie W.
10 percent owner |
- 15780
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 20.4 K USD
|
Kreis Leslie W.
10 percent owner |
- 4185
|
4.87 USD |
|
8 months ago
Feb 27, 2024
|
Sell 20.5 K USD
|
Kreis Leslie W.
10 percent owner |
- 4649
|
4.4 USD |
|
8 months ago
Feb 28, 2024
|
Sell 33.5 K USD
|
Kreis Leslie W.
10 percent owner |
- 6909
|
4.85 USD |
|
8 months ago
Feb 29, 2024
|
Sell 8.92 K USD
|
Kreis Leslie W.
10 percent owner |
- 1832
|
4.87 USD |
|
10 months ago
Jan 17, 2024
|
Sell 172 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 40893
|
4.2 USD |
|
10 months ago
Jan 17, 2024
|
Sell 52.6 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 12521
|
4.2 USD |
|
10 months ago
Jan 17, 2024
|
Sell 23 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 5475
|
4.2 USD |
|
10 months ago
Jan 17, 2024
|
Sell 172 K USD
|
Kreis Leslie W.
10 percent owner |
- 40893
|
4.2 USD |
|
10 months ago
Jan 17, 2024
|
Sell 52.6 K USD
|
Kreis Leslie W.
10 percent owner |
- 12521
|
4.2 USD |
|
10 months ago
Jan 17, 2024
|
Sell 23 K USD
|
Kreis Leslie W.
10 percent owner |
- 5475
|
4.2 USD |
|
11 months ago
Nov 29, 2023
|
Sell 315 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 91708
|
3.44 USD |
|
11 months ago
Nov 29, 2023
|
Sell 185 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 53640
|
3.44 USD |
|
11 months ago
Nov 29, 2023
|
Sell 315 K USD
|
Kreis Leslie W.
10 percent owner |
- 91708
|
3.44 USD |
|
11 months ago
Nov 29, 2023
|
Sell 185 K USD
|
Kreis Leslie W.
10 percent owner |
- 53640
|
3.44 USD |
|
2 years ago
Nov 08, 2022
|
Sell 583 K USD
|
Kreis Leslie W.
Director |
- 132575
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 442 K USD
|
Kreis Leslie W.
Director |
- 100380
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 258 K USD
|
Kreis Leslie W.
Director |
- 58711
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 179 K USD
|
Kreis Leslie W.
Director |
- 40586
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 78.1 K USD
|
Kreis Leslie W.
Director |
- 17748
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 583 K USD
|
Fletcher Aaron G.L.
Director |
- 132575
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 442 K USD
|
Fletcher Aaron G.L.
Director |
- 100380
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 258 K USD
|
Fletcher Aaron G.L.
Director |
- 58711
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 179 K USD
|
Fletcher Aaron G.L.
Director |
- 40586
|
4.4 USD |
|
2 years ago
Nov 08, 2022
|
Sell 78.1 K USD
|
Fletcher Aaron G.L.
Director |
- 17748
|
4.4 USD |
|
2 years ago
Sep 02, 2022
|
Sell 6.63 K USD
|
BIOS Advisors GP, LLC
director: |
- 1275
|
5.2 USD |
|
2 years ago
Sep 02, 2022
|
Sell 6.63 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 1275
|
5.2 USD |
|
2 years ago
Sep 02, 2022
|
Sell 26.9 K USD
|
Fletcher Aaron G.L.
10 percent owner |
- 5170
|
5.2 USD |
|
2 years ago
Sep 02, 2022
|
Sell 6.63 K USD
|
BP Directors, LP
director: |
- 1275
|
5.2 USD |
|
2 years ago
Sep 02, 2022
|
Sell 6.63 K USD
|
Kreis Leslie W.
10 percent owner |
- 1275
|
5.2 USD |
|
2 years ago
Sep 02, 2022
|
Sell 26.9 K USD
|
Kreis Leslie W.
10 percent owner |
- 5170
|
5.2 USD |
|
4 years ago
Jun 11, 2020
|
Bought 150 K USD
|
KEYSER D JEFFREY
Director |
+ 10000
|
15 USD |
7. News
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
seekingalpha.com
- 1 week ago
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on.
businesswire.com
- 1 week ago
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight's management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and bra.
businesswire.com
- 1 week ago
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.
businesswire.com
- 2 weeks ago
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe.
businesswire.com
- 3 weeks ago
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal in.
businesswire.com
- 1 month ago
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that the company has been granted three rare pediatric disease designations (RPDD) by the FDA. Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (.
businesswire.com
- 1 month ago
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.
seekingalpha.com
- 3 months ago
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma's drug candidate LP-284 ((+)N-hydroxy-N-(methyla.
businesswire.com
- 5 months ago
The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Valued at about $79.3 billion at the moment, it's expected to balloon to $503.4 billion by the time 2030 rolls around, according to Statista.
investorplace.com
- 5 months ago
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024. “Our company made meaningful progress across multiple clinical trials and in furthering our AI platform this past qua.
businesswire.com
- 6 months ago
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
PARIS & DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover bi.
businesswire.com
- 6 months ago
8. Profile Summary
Lantern Pharma Inc. LTRN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 38.2 M
Dividend Yield
0.00%
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Contact
1920 McKinney Avenue, Dallas, TX, 75201
https://www.lanternpharma.com
IPO Date
June 11, 2020
Employees
21
Officers
Nicole Leber
Investor Relations Associate, Finance & Administrative Coordinator
Dr. Marc C. Chamberlain M.D.
Chief Medical Officer of Starlight Therapeutics
Mr. Panna Sharma PH.D.
President, Chief Executive Officer & Director
Mr. David R. Margrave
Chief Financial Officer & Secretary
Dr. Kishor Gopaldas Bhatia Ph.D.
Chief Scientific Officer & Scientific Consultant
Dr. Peter L. Nara D.V.M., M.S., Ph.D.
Co-Founder & Advisor
Mr. Ernest Kitt B.S., M.S
Head of Clinical Operations